bpc-157 pharmacokinetics half life Frontiers How Long Does BPC-157 Stay

What the Research Shows In the STEP 1 clinical trial, published in Diabetes, Obesity and Metabolism (Wiley), participants receiving semaglutide 2.4 mg once weekly achieved an average weight loss of 17.3% over 68 weeks, compared with 2.0% in the placebo group

slow metabolism myth: why energy balance and protein matter most for fat loss [1:09:45]

Also, there was an increase in stillbirths and a decrease in neonate survival starting at 0.03 mg/kg/day (0.3 times the human 5 mg dose), while the number of viable newborns and pup body weight on postnatal Day 7 were decreased at 0.1 mg/kg/day (equivalent to the human 5 mg dose)

But the syringe maxes out at 50 units (0.5mL), which limits the doses you can draw in a single pull